PMID- 34953482
OWN - NLM
STAT- MEDLINE
DCOM- 20211228
LR  - 20220531
IS  - 0125-877X (Print)
IS  - 0125-877X (Linking)
VI  - 39
IP  - 4
DP  - 2021 Dec
TI  - Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events.
PG  - 215-230
LID - 10.12932/AP-110521-1129 [doi]
AB  - OBJECTIVE: To report an overview of dermatologic adverse events (AEs) related to 
      biologics used for psoriasis and compare common dermatologic AEs across different 
      biologic classes. DATA SOURCE: A comprehensive search in MEDLINE via PubMed from 
      inception through June 9, 2021, was conducted. STUDY SELECTION: The selection 
      process was performed independently by two reviewers. Studies were eligible if 
      patients were diagnosed with plaque-type psoriasis, were treated with biologics, 
      and had >/= 1 dermatologic AE. RESULTS: A total of 1023 records were identified, 
      and 127 studies were included. The incidence of dermatologic AEs was 4.17% for 
      tumor necrosis factor-alpha (TNF-alpha) inhibitors, 9.49% for interleukin (IL)-12/23 
      inhibitor, 12.40% for IL-17 inhibitors, and 7.37% for IL-23 inhibitors. 
      Biologic-related dermatological AEs can be classified into allergic skin 
      reactions, inflammatory skin diseases, skin infections, skin neoplasms, and 
      miscellaneous AEs. An evident class effect was observed. Skin neoplasms (1.45%), 
      mainly nonmelanoma skin cancer (1.36%), predominated among TNF-alpha inhibitors. 
      Allergic skin reactions (6.25%) were frequently reported with IL-12/23 inhibitor. 
      During treatment with IL-17 inhibitors, skin infections (5.01%) were common, and 
      the most common was driven by mucocutaneous candidiasis (4.85%). Inflammatory 
      skin disease (2.32%), mainly eczematous eruptions (0.84%), dominated in IL-23 
      inhibitors. CONCLUSIONS: A predominance of specific dermatologic AEs appears in 
      distinct biologic classes due to their different specific targets of action. 
      Further study is needed to understand the mechanisms of these potential AEs, 
      which will help in their management.
FAU - Palakornkitti, Pasita
AU  - Palakornkitti P
AD  - Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Nimmannitya, Kulsupa
AU  - Nimmannitya K
AD  - Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Rattanakaemakorn, Ploysyne
AU  - Rattanakaemakorn P
AD  - Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi 
      Hospital, Mahidol University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Thailand
TA  - Asian Pac J Allergy Immunol
JT  - Asian Pacific journal of allergy and immunology
JID - 8402034
SB  - IM
MH  - Biological Therapy
MH  - *Dermatitis, Atopic
MH  - Humans
MH  - *Psoriasis/drug therapy/epidemiology
EDAT- 2021/12/27 06:00
MHDA- 2021/12/29 06:00
CRDT- 2021/12/26 20:20
PHST- 2021/12/26 20:20 [entrez]
PHST- 2021/12/27 06:00 [pubmed]
PHST- 2021/12/29 06:00 [medline]
AID - 10.12932/AP-110521-1129 [doi]
PST - ppublish
SO  - Asian Pac J Allergy Immunol. 2021 Dec;39(4):215-230. doi: 
      10.12932/AP-110521-1129.